These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31343994)

  • 1. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
    Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
    Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
    J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
    Wehkamp U; Stern S; Krüger S; Weichenthal M; Hauschild A; Röcken C; Egberts F
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1301-1308. PubMed ID: 29744662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
    Walsh NM; Fleming KE; Hanly JG; Dakin Hache K; Doucette S; Ferrara G; Cerroni L
    Hum Pathol; 2016 Jun; 52():190-6. PubMed ID: 26980039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
    Guénolé M; Bénigni P; Bourbonne V; Lucia F; Legoupil D; Pradier O; Misery L; Uguen A; Schick U
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2569-2578. PubMed ID: 34115240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
    Lipson EJ; Vincent JG; Loyo M; Kagohara LT; Luber BS; Wang H; Xu H; Nayar SK; Wang TS; Sidransky D; Anders RA; Topalian SL; Taube JM
    Cancer Immunol Res; 2013 Jul; 1(1):54-63. PubMed ID: 24416729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
    Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
    Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
    Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.
    Pulliam T; Jani S; Goff PH; Bhakuni R; Tabachnick-Cherny S; Smythe K; Seaton BW; Tachiki L; Kulikauskas R; Church C; Koelle DM; Nghiem P; Bhatia S
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma.
    Nakamura M; Nagase K; Yoshimitsu M; Magara T; Nojiri Y; Kato H; Kobayashi T; Teramoto Y; Yasuda M; Wada H; Ozawa T; Umemori Y; Ogata D; Morita A
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.